HAE - Earnings call transcript Q3 2018 | Haemonetics Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q3 2018 Haemonetics Corporation's Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. And as a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Gerry Gould, Vice President, Investor Relations. ahead. go Please

Gerry Gould

Bill morning that Haemonetics' Good webcast. you joining forward-looking business and for joined President David Thank our statements. remarks of quarter and today fiscal for Plasma CEO; President Simon, third by Please and CFO; XXXX us and today Wilson, note you. unit. Chris thank Burke, our conference I'm include call will

results differ materially may results. actual Our anticipated from

X-K factors that filings available could cause filed differ our to in is release Form with that the and concerning results in SEC. we materially other the and quarter to This XXXX information third year-to-date we make reports earnings and Investor today our morning, website. Additional periodic our fiscal posted we Relations

two on our with Initiative refer and Bill highlights business. Then tables guidance. Chris and we business we'll that served our David the Plasma strategy, will Complexity our discuss in Today, take markets, posted questions. elements our your to will will information our performance, Reduction We of financial our within call. also and discuss trends

hand SEBRA benchtop gain fiscal excluded from Also, as as upon In we we third XXXX legal Tax with charges Consistent call turnaround we from the to the excluded sale turn charge today. earnings, which charges, the of a their and our we'll of quarters excluded and and XXXX, well charge. results. restructuring line items, from our to financial charges and fiscal size, our past have Reform onetime the income adjusted which over In realized XXXX, cost about expenses. talk impairment items treatment our I Chris, results resulting we practice, certain like I XXXX, by in year-to-date fiscal and and and nature year-to-date mention amortization comparability Before of fiscal the certain affect non-cash the certain U.S. deal-related of would the adjusted results, excluded in sealers. year-to-date we financial adjusted

items. In we Plasma revenue XXXX bear the Finally, included total SEBRA revenue fiscal $X.X revenue. and mind in $X.X business excluded that year-to-date million and revenue the please and SEBRA no quarter results, Today, our comparison, effects By will include considering X-K excluded respectively. third XXXX we cite of million organic posted effects fiscal of unit tax excludes the impact of to details website. provided divestiture of of with been excludes our periods same the are revenue third comparisons currency. and Further growth, year-to-date have and the of fiscal which quarter amounts XXXX our Investor Form and Relations including the in excluded SEBRA Haemonetics

like press over I'd sheet complete and website turn statement that, well also and as of reconciliations adjusted included reported to flows, results. balance and With and P&L Chris. cash as release our summary a of it Our to

Christopher Simon

Thank you, XXXX our performance, taking will morning, we and long-term discuss to fiscal our the are Good for year-to-date Haemonetics quarter transformation welcome growth. Today, and for to position revised Gerry. outlook everyone, call. we our and advance our quarter actions and third

goal our turnaround, those accelerated delivering superior and creation are on segments against value achieving multi-year our executing of segments our in in progress centered results. positions and continued shows attractive year-to-date leading growth performance Our we strategies

the elements increased adjusted quarter benefit We benefits. growth, earnings net we favorable outstanding in had this Tax and Plasma our X% Our operating of dilution additional earnings to remaining from increased performance Plasma Organic XXXX currency, had increased our three expectations the XX%, on later. non-operational adjusted moderated up XX%, some the growth, results last quarter, in of third in third $X.XX generated per organic surpassed our Bill growth foreign consider year-to-date, revenues share, health business the and Center making. We generating validating and are quarter increased performance X%. aside, capability also Hospital $X.XX per our free Adjusted from underlying the grew revenue third operating Blood X%, providing combined revenue $XX to XXXX. X% had from of items for a revenue including provide strong detail income fiscal in fiscal X%. will company. that the and of our individual Center quarter, we Reform, as These X%. flexibility the performance adjusted further quarter. items Productivity $XXX have with contributed $X.XX we in solid our Year-to-date by growth Blood grew million of Hospital XX% year's million over a to meaningfully income flow last X%. in business a an share We third declined organic combination approximately decline third was year's and while adjusted cash demonstrate investments share revenue non-operating cash gains count. U.S.

turnaround and supply to taking expected of changing a all this is of performance and a To to but global laggard, are same reduce manufacturing as in parts date, been corrective the complexity. improve not organization further pace. However, be actions rapid has the at magnitude, are we

business now me Let to turn our units.

together, a defined and organized corporate play to are our business are three synergistic. each around focused role We units, customer-centric they financially in portfolio, has

both are U.S. by with the the growth where of from innovative in been to an third has company. designed investment Plasma our software, is about It increased focused it donor platform. roll improved out straight PCS remain excited value create disposables yield to and revenue key experience, and to through quite customer for meaningful NexSys plans a was We area our particularly on and start driven Let's growth quarter and

know interest are level is in and a plans these initiatives. on that fully Our key high of there we track

call Wilson, unit, for So, I'm over the a of to pleased turn Plasma our business further President David update. to

David J. Wilson

medicines the and provide demand that significant on new to collection excited advance NexSys toward derived confident brand to unit in who blood for platform PCS. we are growing processing implementation plasma. a I'm our from our will innovation commercial space, Chris. value Plasma Thanks, human lead is the business the to as customers of working and Haemonetics built meet I'm global

Let me the for begin platform. new restating our value proposition by

or, new provides these opportunity reduce We our productivity firmware; the yield platform. and the software NexLynk customers it, disposables; It by NexSys and for System; embedded experience. to software; will to consists time. support additional a innovation we referred and Collection previously helping Plasma donor to offer components collection Each of of DMS, management the the of technical ensure donor the uniquely its service. liter plasma customer as cost donor, throughput, over per is quality center plasma compliance increasing collect positioned help overall to a Haemonetics enhancing improving and

NexSys Beyond PCS benefits individual integrated more the the our valuable for even the platform of these and foundation. customers is is components, for Haemonetics.

We than as yield to donor the device, embedded a designed device. NexSys experience software two maintain, build upgrades. overall more is it in decades have leader the plasma easier operate the and through harnessed planned design collection smarter to was plasma and per of and increase space to

on the PCS also XXX(k) CE recall embedded You'll expect device cleared FDA this NexSys July. was we a that Mark spring. the in We and the submission the software for platform anticipate

programs. DMS will support accommodate open architecture all an PCS NexSys to format Our

it pleased while because However, by fully fit for PCS software easier, will NexSys optimal NexLynk need standards paperless a Today, America We the we NexLynk is quality of was the DMS are bowl, reducing and highest worldwide. North March largest our XXXX, total highest what using selected now for and on With to designed confident its compliance NexSys In PCS collections and U.S. the to combination provided seamlessly the time. donation collection provide while the customer that all supporting installation our it productivity. completed making Haemonetics DMS and leverage our it also bidirectional and industry our system. regard DMS software quality the remain appointment we our with NexLynk are of the Plasma the harness this And our that DMS. the we customer. the we translation facilities standard It compliance, device. kits is today. donor providing disposables, majority developed and that distinctive bottle to will integrated successfully of truly of the disposable satisfaction Haemonetics produce insights NexLynk customer the makes manufactured device. center have The between DMS eliminates system, based DMS for boost the is precision. are and of conducted deep a level increased also plasma

Additionally, support we design are enhancements and innovating on both future to manufacturing growth.

customers. our be to experts providing matter teams, assets. major a and remain We consider experience and of meet satisfaction and needs is backed the committed working computer by chain and our Relationships in-house technical to we agents, customer-facing technical engineers, service superior customer Finally, paramount. of caliber to science supply support customer

operations. Beyond build customers we best center scale their overall as options that, centers part in are donor we that and provide to services help service We leverage increase that our to offerings. capability practices to and evaluating benchmark productivity platform of provide this best-in-class

move of supply, and launch. including global areas contracts, platform, manufacturing commercialization phased strategic forward focus milestones, we commercial distinct customer first toward of As are launch the there our logistics and new regulatory including of

critical me Let each elements. of status these for a provide

regulatory on As are track. mentioned, milestones I

programs our manufacturing discuss. we customer majority programs calendar XXXX. within which of underway participate our being and device Donor ramp-up programs, will in is experience and accumulating begun to which center customers have the for these now some I inventory, are We of used experience are our expect

a are our experience work previously our use to the center to and point begun of customers a next-generation negotiations. pace toward experiences. referred we to intended implementation evaluate have These use. enable for these procedures, contract our a As FMRs, LMRs, seamless customer of device, platforms. at commercial to supports clarification, transition customers to Collectively, We've preliminary also and will rollout the platforms new programs ensure that internal advance

approved We beginning our for first NexSys released. implement contract after expect PCS software is summer and the customer to embedded XXXX

truly PCS. first I'll will back realize financial course. that on is a Overall, on turn at Haemonetics. timelines it communicated, focused now, our to previously our be As are benefit time future. This constitute I'm And NexSys opportunity to our on great Chris. to

Christopher Simon

but it enthusiastic growth Thanks, about David. I our driver. how are Plasma, is not hope is only clear it we

to versus grew the Hospital quarter, acceleration prior business, year. last a in Moving good our and revenue quarter X%

versus strong Xs fiscal and improving international about TEG XX% in growth results in driven was XXXX. XXXX sales as North third in In both at continued TEG America major double-digit as disposables, quarter, in track year-to-date on well TEG key by in we markets. performance is growth our the revenue drove and Our results TEG quarter markets. the

improvement differentiating growth Hospital about and markets critical beginning role our We long-term are our well enthusiastic from remain markets. our especially for most the organization specific see commercial important to We outside as changes, and in the as play ongoing TEG. sales personnel U.S. strategies products the for business, prospects

for TEG, and KOL as multi-center Advisory trials well clinical We representatives. Committee, force, sales continue multiple a BloodTrack ongoing to our Scientific our invest meaningful in as including support from study of expansion clinical

guidance been which of Center past both in factors blood estimates X% original by revenue Turning to commercial stable to us to fit-for-purpose in validated rates in enabled business maintain X% our The With and The America, business relatively at to the about and the this appear market Blood accordingly of increasingly well have business demand the making of investments negative North puts as In us been performance our and on range. by XX% focus income business with quarters, that select lean, of several and has these of backdrop, an end customers, allowing for the confluence with our consistent a negative overseen manufacturing, X% declines year-on-year favorable are for the with disciplined decline we volume center. in decline corporate is our the unit, moderating our rate operating this own is choices managing year-over-year. products. units as is of business.

efforts performance. company-wide underway have multiple We to drive

announced Initiative to in drive forward planned. XXXX in is productivity resources moving invest a is Reduction of growth. processes It Complexity improve effort to comprehensive November our up and to Importantly, as free

teams work and our base. changing our cost are way We underlying fundamentally reducing the

the to are transformation. enabling a that of variety We initiatives important ramping up are

to streamline operating our continue We model.

reducing and of products. quality cost the operations, on safety focused ensuring further teams in have We while our our

Head next are rollout, back-office for is us stages as on our are We those proceeding agenda. clinical, are development. our that planned of product make our freeing many up in NexSys advance focus as R&D, share distinctive. innovation supply disruption. rationalization. minimize customer-facing in mind country progressing of and our clinical market ensure This capacity in manufacturing network, outsourcing optimizing the Savings way continuity resources and fuel network and and of and and our and thoughtful new activities capacity changes position, a SKU to and we underway, we advancing fund sales the will our trials and activities future pipeline, important standard the as of Strategic customer well us to PCS are count includes investments care bolster and that people

delivering are changes. these us processes deliver in They're patients improving customers, building value providers. greatest differentiate the to employees healthcare that the new Our capabilities marketplace and donors, and and

As to governance. the remain committed we deliver we of these changes, good principles

refreshment. those One principles of is

board As our saw in announcement, is a because and of member our experience. healthcare months, authorized a has mix possess selected $XXX board. you share rejoined Today, Zane strong recent we to were repurchase strategic industry past million all join fourth they Ellen She the the of program. in that our whom XX announced operational,

an and share dilution reversing prudent manner. to are We in committed opportunistic

we the the repurchase, our plans prioritizing next investments as well our as business, will at of growth. for this inorganic share strategy addition In context allocation look opportunities for in in capital year, to

take competitive several U.S. globally Reform, it for for of and Bill Regarding I believe Haemonetics. a is reasons. for it through us, us the means what Tax details more will the positive net makes it But you

in a the competitive. flexibility, operating and operations it us tax gives the field so that manage can be levels playing First, to we best from way perspective our

integral to Second, that capital benefits overseas are plans. reward in and cash will for making our associated more outset. flow with efficient necessary depreciating repatriate the fully it This company the investments is investments there immediately at are capital to cash,

capital plays for IP incentives reduces rate to of which value of enhances lower significantly strong our and strengths. our a M&A. Overall, clearly U.S.-based cost tax are the U.S. investments and there anticipated potential our Third,

our upper for guidance revenue ends slightly and versus below with strength positive On Hospital to Plasma the both Blood of we year to on falling now be and a our revenues guidance reaffirmed ranges We of range. estimates. currency growth results, of previous unit our the the fine-tuned basis slightly year-to-date we previous constant Center flat business expect prior at the ranges,

we be range $X.XX XXXX fiscal which accelerated earnings necessary we original will guidance. share share accelerate to expect fiscal In per of in into account takes beyond. above We a prior quarter guidance focused the for steps investments to to some prepare Implied adjusted $X.XX our conclusion, is and $X.XX, above fourth taking make and XXXX are targeted XXXX per earnings $X.XX for growth. fiscal our to growth new on

services patient costs. improve and care healthcare products our Our and reduce

on We believe the work build to the us and right to the and to the by turn products plans, that, are about processes, this, it right it call supported Haemonetics. With passionate continue and and it right motivates over healthier mindset because I to we I'll have like right someone's and high-performing people that strategy life a depends the does. Bill.

William P. Burke

dollar and Chris, and percentages comments. with I'll income that in the amounts our we refer you, Please revenue release. everybody. We to website the Thank to provided good to posted my refer the morning, in two earnings our link specific tables derive

rates revenue are I all growth will discuss identified, organic. we As

and growth, from year-to-date fiscal investments. expansion modest higher XXXX earnings Third including leverage margin and included operating gross revenue quarter adjusted aside the expense performances

We also delivering flow investments cash and and the had year-to-date. free in above grew XX% productivity we and we XX% income initially third are planned. growth quarter Adjusted what operating making

on points was up XXX the quarter XXXX third XXXX Included in over up fiscal the fiscal XX.X%, basis margin margin of the and $X.XX currency improved operating adjusted same is of share year, margin XXXX adjusted of third per while up up prior year-to-date points the the XXX the net period quarter, over XXXX. in fiscal points and operating basis quarter was basis. of of $X.XX improvements basis XX.X%, third to basis XXX result a quarter fiscal in points Our year-to-date XX%. third XX%, the XX these earnings The a of improvement in benefit year-to-date, a operating

specific comments, positive noted to in Chris' approximately we a opening impact. quarter had items we adjusted three referencing our As third earnings netting in in press and release this $X.XX the

our per Tax to added earnings. rate share First, Reform a that of adjustment year-to-date the $X.XX passage adjusted U.S. to led

foreign by reduced currency Second, third, outstanding $X.XX. share count And another favorable earnings added adjusted $X.XX. increased

in remaining operating of items, $X.XX quarter, our the these the from we demonstrate Excluding the third in $X.XX performance $X.XX three consider last up share, to year's third per company quarter.

declines strong up the get In revenue remain into X% and disposables continued expected organically. XXXX, was disposables basis, the in was quarter solutions. behind from year-to-date. organically. and third Now, Plasma was is Plasma the our fiscal a up in Plasma of the America details year-to-date XX% offsetting and results. to I'll revenue quarter software third Plasma of strong up as results North in fiscal X% revenue Revenue X% XXXX up liquid On

Plasma sequentially had the a On TEG the year-to-date second we level following growth quarter. quarter about revenue within XXXX growth in and X.X% business, The that the fiscal versus continued delivered confident TEG prior is of third X%. the Processing the high by Plasma success organic plasma collection end deliver fiscal remain third for Hospital TEG to X.X% updating be XXXX, to of in biopharmaceuticals. of year driven to are the Cell fiscal revenue up quarter. strong at X% revenue X% market strong which X% Also, continues an our growth, in year-to-date increased year-to-date We our about expect the performance business revenue of half teens was geographies. an to plasma-derived third growth commercial basis, our previous XXXX disposables highly range end We revenue while approximately of China. our at better low the quarter half continued which XXXX, in in market or X%. guidance underlying all growth. in we approximately growth demand both On across growth encouraging growth Hospital basis, was in

For revenue Cell the flat. year-to-date fiscal XXXX, was Processing

Year-to-date platelet was XXXX. long fiscal term. of over the the updating declined quarter to units XX% fourth and Management levels our are X% in collection recent not quarter the range. guidance the fiscal we that Management year-to-date Japan fiscal year-to-date the mostly a outside the growth, declines so expected in moderation the XX% announced X% U.S. up were the third fiscal are continued fiscal Hemostasis third contracts collections, X% the rates in Blood in quarter expect of revenue below expectation fiscal our expect in mostly growth quarter cell collected the in in U.S. continue XXXX. down from of rate of Whole Management third in X% of These revenue at fiscal partly quarter pricing in to of will XX%. technology fiscal due the in arrangements maintain slightly to exceed make and and this XX% second of and quarter decreased XX% our continue XX% to blood third double-dose trend unprofitable revenue considerably competitor's disposables in previously experienced outside decline both XX% the by is disposables in customer are revenue Hemostasis we for grew for techniques XX% included flat the moderating year. XXXX growth quarter so rate We disposables year-to-date end year-to-date decline XXXX of Red Hemostasis XXXX remainder approximately consolidation. third third continued XXXX shortfall will the that collection inherent XXXX year-to-date, moderated Hospital fiscal of Japan. adoption we and Center to double-dose previous declines the the it revenue exits to collection U.S. and low we quarter similar Approximately X% in and from business intentional and lower mostly design was as Center by fiscal attributable The Blood XXXX. customer the Platelet XXXX,

to previous guidance double-digit low We of are of the XX% Center in updating customer fourth of to guidance a an our approximate to the revenue Center X% decline. favorable approximately XXXX year third as decline quarter a dollars quarter range our are fiscal implies due revenue fiscal amounts. Blood percentage quarter to order we strong patterns. This Fourth and XXXX expected second revised X%, Blood end decline a the had quarter fourth unusually prior

performance. the XXXX points XX.X%, quarter. drove fiscal gross points had adjusted prior absence benefits productivity prior XX.X%, inventory quarter We Third third prior XXX product Year-to-date gains year. was above the in was adjusted of charges that year of XX basis profit gross mix, improved profit the basis above year the

a adjusted the we stabilizing will investment resulted million by from of to points supply, expenses operating increase in from improved revenue. lower year-to-date basis, operating direct savings prior or our acceleration annualization for focus on efficiency half the continue cost or year-to-date the The offset of expenses XX.X% fiscal XXXX investments. second of current compared savings X%, global by the cost year X% year On productivity and performance. XXX fiscal While in spending basis and Adjusted at more short fiscal The $X with higher was was we year. with projects operating third the to compared which points basis basis $X year XXXX million, incremental of than manufacturing increased of a revenue. the XX of planned of operating declined anticipated expenses and on and operating goals the a quarter expenses XX.X% result XXXX in of fall

investments impacting and of $XX in fourth million representing We We $XX to prioritizing increase guidance are operating in revenue expenses, $X.XX the an XXXX, the to continue million compared or strategic of accelerated per improve fiscal per we $X.XX opportunistic and tax accelerate Including share $X.XX investments, to meaningful directly share after spending fourth growth. we projects incur to $X quarter. intend spendings previous million that evaluate anticipate other to to future investments the quarter. will ensure planned of

and benefits share year productivity to activities per $X.XX prior to XXXX. of deliver will expect $X.XX continue continuing restructuring our We of FY benefit that in

to quarter was the lower year the year XXXX, reflect Also, Tax adjustment of to full the year. adjusted Reform. expense unusually prior The geographic catch-up significantly to earnings in third tax we to mix. was a quarter quarter on U.S. than income of of rate an the year-to-date an third expect due tax provision rate Our lower impact fiscal XX% year-to-date rate our for XXXX we third tax unfavorable fiscal prior high now with due had the

tax XXX was fiscal same adjusted points geographic of than XX.X%, provision XXXX on Benefits more about period basis earnings prior the year-to-date continuing Our a year. impact lower shift income offset Tax the than the toward U.S. Reform mix in the of of U.S.

income We expect tax in tax adjusted fiscal our Consistent of million million net year-to-date of and of consisted full fiscal $XX million expense Initiative. and to severance and million policy, to industry a was Adjusted in XXXX million approximately year-to-date rate. own of was year by XXXX quarter earnings. million earnings. and fiscal our we In adjusted compared million anticipated cost excluded deferred XXXX. Reduction third a recorded and $XX with cash charges flow the our the with quarter. our fiscal tax This balances approximate $XXX reform, from year-to-date million tax largely fiscal restructuring disclosure our free $XX $X the excluded practice our tax of in XXXX third third was adjustment turnaround the we quarter rate $XX incurred $XX transition Complexity common Upon provision $X enactment XXXX, of third quarter from

million strong position improved the restructuring $X.XX generation being end We approximately funded our results, XXXX, of strong the of cash restructuring materializing of to debt, divestiture in from before for guidance cash $XX timing adjusted costs. lead very disciplined We We finished EPS a we expect XXXX. free fiscal on continue fiscal combination programs. million $XXX new share with capital SEBRA increased XXXX and flow the now of and $X.XX fourth addition, Reduction an flow fiscal expenditures, million instead since turnaround In partly cash we third benefit. capital tax expectations. $XX full and performance, favorable million $X million in essentially $XXX range The and turnaround forward by strong of from employee moving repaid investment to in of $X.XX and a proceeds year some to million year. increase realized operating announced is activities quarter we as fourth hand, of $XXX management, $X The days net asset quarter. the a fiscal The the quarter of planned. offset including Initiative million We of $X.XX, XXXX increased to by our consistent implied planned XX quarter over-performance, in third Complexity to levels ago with working is $X.XX

So, I offer a comments. few brief will just

questions. minimal our expect second, reach And for million are be fiscal of run savings First, expected benefit your $XX in end full rate we affirm fiscal the annualized we a expectation to year implying that And by fiscal to of in XXXX, to we savings XXXX. XXXX. now, will proceed

Operator

from our Lewis Morgan of first And David comes Stanley. question

open. now line Your is

David Ryan Lewis

few thank questions for and you. me. A morning, quick good Well,

one that spending actually fourth quick earnings in that's the could on quarter of question quarter. I'm sort commentary fourth morning step said last third light and could how financing, Bill, had next of relative walk quarter up about thinking program, you years. confirm third-party that up, so Just use of repurchase of be sort one you have for higher talk and one the the and maybe spending the financial just earnings, purchase case. this for But sort EPS just now the couple after the a program, your potentially longer this that. not it's coming two going of no assuming than of quarter debt cash of about Then, priorities these for Chris. was $XXX you're years? you, refinancing surprise Here then, And you next Chris one us. capital to more third? million sort then, more from to going that us through, where you Can is

William P. Burke

related I the higher QX. say correct. to of So, be slightly spending think this less get that we'd that investments the like slightly those. and the be with but And we QX did QX to made do on we've I also, would different. up QX QX is expect essentially but pushed to you to In different, anticipated QX, caused said timing into be to – QX. and QX, the QX David, we other some has QX, spending, determination what investment And that's comment the speed than

at In implied $X.XX. QX adjusted And, addition, in some earnings, $X.XX unanticipated as Tax to count, were you can that $X.XX. time Reform there out one which essentially EPS and share have more $X.XX that becomes such the point for that number again, I should items FX we look and just and EPS, net is the the QX

David Ryan Lewis

the Bill, we of just than of forward the and end obviously, capital years. much. more high the frankly then, to And contracts market priorities, obviously sounds in end summer And then, for NexSys than, guidance traction raised It you three about necessarily. expect range. you expecting? you as the see Okay. is that's so the demand Plasma like Chris, couple But, which probably here we some earlier what months can Thanks from move were next

William P. Burke

Okay, David.

of part the actually some as So, of now. discussions we're resource our with long-term in capital banks planning,

we have we capital we'll dilution mindful days, this we'll we hoping of interest progress obviously, refinancing of part of But over we'd structure through be accelerate so, mind the dilution. the through starts next too But quickly. schedule to the XX-plus further by amortization very, that like favorable to also switch million planned year, as done when and soon environment as as and over and our as rate planning. we're doesn't in the that with our planning, capital this have end Our share $XXX very get possible repurchase go

Christopher Simon

all for part Well, on Yeah. our value-creating are year and planned fund We to inorganic We'll contemplated fully pick focused to even obviously make just beyond. allocation announcement. part and very that's important on as obviously our of M&A, this. to look that. allocation growth continue in for planning of all and going We'll capital through is investments at this of opportunities continue We're proper I'd an next strategy. our up which

particularly in to the we're for terms a definitely going In North demand the we're That's Plasma, really at of and kits experiencing, we underlying be of of globally range. now feel that combination in but America, particular. high-end the

more as share favorable we're have And forward. lineup mix more collecting There's well. product we're as that benefiting and are customers So, leader. that then, our we driving just benefits some the

and it. So, about good working is the strategy we're feeling

on of logistics, terms here changing the we room, get certainly with we manufacturing we're into fully Wilson rollout essentially timeline, as ramp, proceeding and and but We're the schedule. where the planned. actual in all from were. can negotiations, Regulatory, not David In this customer

Operator

And comes question from next of our Craig-Hallum. Thank Matt Hewitt you.

Your now line open. is

Matthew G. Hewitt

for the Good morning, Thanks gentlemen. questions. taking

Christopher Simon

Hey, Matt.

Matthew G. Hewitt

call this bit or run had new Center like me. one years It Are run than sounds a about the there. rate? two to the been thinking little Is the should from Or declines next, moderating was close First over Blood have it, a we new we maybe rate? that anticipated. better we so? how be

Christopher Simon

Yeah.

number So, we America transfusions of reduced rate certainly of the decline have in benefited North in by a in particular.

X%. had X% we is excuse we're to factored X% is of What what minus minus X% decline, to So, originally to closer experiencing in me. and we're seeing kind

Advisory a and which And Committee looking the But, minus and period. Scientific you're healthy to experts components geographies about at. we're around I think the that, appears X% it in talking both you're to it. on depend based range current that poll hold upon and succeeding we there's individual our benefiting for does the from customers, which our minus and As X%

continued We business that to have also manage quite purposefully.

that us us our more base appreciably are that customers. we we've have, represent and to that contracts are individual continued favorable of business contracts for sustainable the more for and a So,

William P. Burke

And said this and some were to that I in the the to And, low my Center cut-offs There this with – teens. order thing year dollars between revenue the opening of what and we rate Matt, and be in QX in QX decline to if the QX about you growth QX look at overall when last do expect generating be year. and Center in Blood one was year. it's in can in timing did Blood equivalent add it QX comment QX, we significant just I that is of

be we than a growth that So, it alarming. see the we've decline will even seen in X% business year-to-date, the greater shouldn't though

Matthew G. Hewitt

in of from income rate being the tax Maybe tax tax pushed remarks, that you me is Great. discussed all for Okay. or – one the device that Thank does the you. clarification medical also the lower all rate, again? that out you. your point benefit prepared that on include is Thank

William P. Burke

that. the from in Again, reduction have for it The in quarter there. we us medical tax Reform a the there's in just device rate, no accounted in So, Tax impact rate. impacts that

We deductible for also of number significant automatically QX, stock had purposes. a are option exercises in tax which

also down. rate So, drove our that

Matthew G. Hewitt

Great. you. Thank

Operator

from Dave Thank of you. And Securities. Turkaly next our JMP comes question

open. now is line Your

David L. Turkaly

Great. Thanks.

sort in of saying for about first will talked in embedded to a software is you're – that. I track in remarks. at – of some be to clear, terms when the terms just remains think trialing, or think negotiate color the now even going And of come be just how the contract how want you'll to software trials I all are this that with any when a want that associated And what the the XXXX. you think of you'll do get you level the verify of expected? lot those on customer You just at on to prepared you of any compares Plasma get high I there's think XXX(k) we'll in commentary summer start maybe somebody you terms in line contracts

Christopher Simon

Thank Dave, it's and direct we question. interest let I give be I'll Plasma. the a response. Chris. the appreciate transparent. understand in David to want for you do We you

or we're directly. level potential competitive for reasons, that answer customer response are to those your some to However, questions David from just confidentiality in questions there the some to going preserve conflict, detail avoid question I'll and of let and refrain

David J. Wilson

the timelines spring. this so, on are Dave, right. file track. Chris. The XXX(k) We'll you're Thanks,

parallel expedited are be of have to an In a full giving conversions. programs. and but FDA. the obviously, donor that, do with will the planning We lot an expect hands customers really center opportunity Those our for in paperwork the center that doing review, get with They device. we are experience experience of some to

into together, activity. It are met and that into thus of learning The well in, space the all on customers from the our of experiences. staff we and and get share live getting the majority we're from feedback a the as with our So, as progress move level you expectations. summer. that's intent to the view eventually, launch donor donors we with to and having timeline then really but Clearly, launch. programs as we that the precursor of a as that office the great far draws an we're high phase that's the starts and we're setting, a specifics the without themselves, has can and centers, preserving I parallel engaged in one excited doing about

David L. Turkaly

Processing Thank And of Carter, at just sort then you if or for maybe the that. for side. looking one Cell he's there,

I think that about guys becoming you a business. growth talked

that. options to the some color I reinvigorate products Cell increase the comment new that But rate potentially were think help on there there. Processing and growth or going any might were that line new

Christopher Simon

Carter Yeah, Obviously, in, it's so script we're Hospital Chris. about the TEG board if elsewhere. in might. I I'll No this stand be the about a morning, talk enthusiastic lot very a across and and

much there. Cell enhanced opportunities. into and very associated they equipment. reach marketplace the Salvage software seeing earlier some other into customer two new for Saver individual with business, face management, year, as to largely on connectivity, and And the Salvage, some that with new the a this Cell focused that different accommodates response the features breathing the life In nice as of we're put In the and lines driving improved we transfusion returns It's the business, challenges that the relevance that. much use advancements we're of benefits different line, terms we're product and Cell

a revenue hardware play will has of helping software with to hospitals terms full management, refrigeration transfusion thing SafeTrace, that actually a that. consort Transfusion thematic a in the to or about the particularly. us two growth and know potential. and So, potential both up be profitability certainly in hard we in interest management, largely in patient forward live venue. we're It's with and some But highest and marketplace, both for management our blood we offering. pushing the their that's help feel its to BloodTrack There's

XXXX we're excited it's as transition to So, come. particularly about accelerated that FY we one growth into

David L. Turkaly

Great. Thanks a lot.

Operator

Jefferies. of Anthony question from you comes Thank next Petrone our and

Your line open. is now

Anthony Petrone

understand And congrats on so Good there, there's Philly being morning. Patriot company intact after Thanks. and fans thing. Super the a good Bowl. the that's I

outlook terms – In on Plasma. couple just restructuring a on then, a and couple Bill and for of tax

expectations, $XX there's the pre-tax portion of be appears invested. sounds that's million it like that just versus costs million, million the and to Just on seems restructuring, to be a incurred $XX it $XX year-to-date of that ahead going savings around to tracking

the XXXX, will rolling and between much So, growth? ultimately two maybe do in then see years you XXXX for savings how and in those reinvested how restructuring be

William P. Burke

But at by get between the amounts what So, not we're Anthony, we two FY what exactly will run on to savings, amount. $XX just we've said the XXXX, are ready rate to reiterate the restructuring that restructuring be related disclose of million to we those is to savings the years, time the program. end

Anthony Petrone

do you will net again expect that's and reinvested? being be of a And of – portion the line that that mix what versus will reinvested of go bottom to

William P. Burke

we we've make the we trial to everything rollout I devices of out we're else Plasma this talk the business, but building about other we're – to going sales as specifically, for David the in made and going that to don't in work continue Hospital investments morning, on spoke as that think going we're Yeah. force, clinical within have about say and that's developments the the force. well to continue sales the

growth. with So, as at up, and look last we'll always come I half any over and to we've investments what we're think to strategically obviously, been change. the said here, those year since no there's try sticking a accelerate I've But,

Anthony Petrone

tax, the Plasma, follow just on then, different on then, important? enough. the be sort good Is of Fair error for is is should to (XX:XX) just is XXXX beyond? that more we donor fourth NexSys Thanks. up hearing I measure there on last just financials, fiscal reduced And quarter rate tax assume that various benefits you terms And color anything and in it management? that mean, are would you of Any can share bringing. a helpful. what yield,

William P. Burke

our year, the tax full have in that the we'd expectation we're that for FY assuming and be is So, XX.X% year-to-date on XXXX. the Anthony, lower we rate,

Anthony Petrone

Thanks. Okay.

Operator

Thank question William next our Blair. you. from Brian Weinstein And comes of

Your now open. line is

Unknown Speaker

in Andrew, get for in there that business better getting needs to sounds you're OUS actually happen But Good On guys. Brian a on what is turnaround Chris, TEG, more to is Hi, confident going point it that to that this morning. order the morning. This else well. like back and is really in?

Christopher Simon

that. his I'm going question in separate Andrew, and go I'll I'm how it through customer to respond, about your just moment. your question. question we're pick had to our I thinking to a on and from then Plasma up going heels just team about Petrone – a and asked answer Anthony David benefits let

Unknown Speaker

Great.

David J. Wilson

Yeah. Thanks, Chris.

Anthony, consistently, One and collect goal value per involving a about cost our the really plasma the to of donor. XXX(NYSE:K) of reduce we focus that's that's submission. liter to Obviously, is the (XX:XX) the benefits. the increase to by prop talked supported So, plasma yield of four

donor compliance. then, to Beyond is be and productivity process industry retention regulated lot key. heavily will and donors ensuring with that, system, that day, donor we throughput, helpful. of around on well, data, get a improving digital center And more paperless of into recruitment a donor lot all focusing a and ability doing activities with their Obviously, then, so very really sensitive that doing quality each

enhancing prop. overall benefit So, has donor a the experience broad to value

the to take reduction and they'll collectively, DMS optimal together, so, support also and (XX:XX). cost to the NexSys that when designed and experience to ability And you have the liter our support work collect at look been the PCS NexLynk a

that's on. So what we're focused

Christopher Simon

David. Thanks, Great.

Christopher Simon

on worldwide. to TEG your question very we're obviously Andrew, about enthusiastic TEG,

this In focus, the prior level think focused. back our and new recall, made was that were commercial organization. consistent And with that configuration, there we the business in you local Historically, terms in was of the may to company trade-offs regionally at the the performance spring, I more pivoted customer-centric then. predominantly U.S., that were unit outside

they fully the TEG that, and focus these opportunizing can mean in products Our what is with marketplace. global like

this largely at have outside the we So, number we and And of early notably well UK, to like have China strategy. markets that, U.S., reconfigured, of seeing a the looking and core that markets, responded a the we're quite focus very this that benefit much delivering. country-based we're are

interesting of growth (XX:XX) reality shoots or is XX%. that It's We handful the we if markets, other plans. OUS look five The potential above tremendous force largest experiencing first our we're green see of have growth and we're at thing, that bold where we there. across markets, getting and rates an put a are you

that. we However, we of our current We're now think forecast can than We And in year of fiscal probably that. not and ago a done get the to like the to pace back ambitious back kind understand excited. was going change year. more we're to that that get

Unknown Speaker

guys. Thanks, Understood.

Operator

our next Company. And question from you. Thank Sidoti comes Jim of Sidoti &

is Your open. line now

James P. Sidoti

me? morning. you hear Can Good

Christopher Simon

sir. Yes,

James P. Sidoti

you your wore jersey yesterday. to Chris, I assume Eagles work

Christopher Simon

glorious I the actually game, attended XX did. Jim, the I minutes all of it.

William P. Burke

has he And just his here. shirt on rub in it to

Christopher Simon

gentlemen were a few There (XX:XX).

James P. Sidoti

be Can guidance aspect, will was XXXX, on to going you one it you're in tax boundaries the you that give quarter. to fiscal fourth it just us I on but tax some is rate for where think than fiscal reluctant know rate, said give you Good. XXXX? in Good. come lower the for

William P. Burke

else saying other what it'll right to we're for lower going than anything now projecting not I'm be than this year. provide that

James P. Sidoti

was higher impacted than quarter had that think expected I kind bit margin of this level or gross Is the this the new were quarters. onetimes of than and couple I then quite a it And a some Okay. you've past the that? there

William P. Burke

because obviously of good of was we took there really the last inventory we and basis, year, On benefits a that mix. charges year-over-year had performance strong

would but savings which gross program pointed in of a portion those we improvement. that is Our where are towards are the of we expectation margin have restructuring in range be we a QX,

see we margin. time, in movement gross upward over So, an should

James P. Sidoti

All Thank right. you. right. All

William P. Burke

You're welcome.

Operator

Thank you. like any conference I'd to for Chris the to session back And that today. turn remarks. closing concludes our Simon question-and-answer for over

Christopher Simon

all. you, Thank

to you. Thank again, business on mark planning the time calendars priorities this At accordingly. we you, for Just that point, we'll playing having Investor during your the time meeting so purposes. anticipate be a our you for that, this today. that change back out heads-up quick can same Day calendaring If given we're many summer, Annual we period. not an Thank you,

Operator

conference. does Ladies program. This in and thank participating today's gentlemen, the for you conclude

Everyone, have disconnect. day. all a may great You

Haemonetics (HAE) 6 Feb 182018 Q3 Earnings call transcript